Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Q1 2026 earnings

Reported April 30, 2026 · After market close

Revenue$156.1MBeat by $11.1M
EPS$0.21Beat by $0.46
Revenue estimate$145.0M
EPS estimate-$0.25

Next report

Aug 5, 2026 (In 6 days)
Revenue estimate$177.5M
EPS estimate-$0.09

Financials

Q1 2026

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$378.2M+2.8%
Enterprise value$801.3M+3.6%
P/E3.3×—
P/S0.6×+0.1×

Profitability

See full
Gross margin54.2%+19.0pp
FCF margin20.8%—

Returns & leverage

See full
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Segments

By product

See full
MCM Product sales$101.8M-35.0%
Commercial Product sales$42.9M-5.3%
All other revenue$11.4M-43.8%

By segment

See full
MCM Products$101.8M-35.0%
Commercial Products$42.9M-5.3%

Versus estimates

Revenue

Q1 2026$156.1MBeat by $11.1M
Q4 2025$148.7MMiss by $68.8MQ3 2025$231.1MBeat by $13.6MQ2 2025$140.9MMiss by $62.8MQ1 2025$222.2MBeat by $3.2MQ4 2024$189.3MMiss by $89.7M

Diluted EPS

Q1 2026$0.21Beat by $0.46
Q4 2025-$0.43Miss by $0.54Q3 2025$1.06Beat by $1.18Q2 2025$0.16Beat by $0.42Q1 2025$0.71Beat by $0.22Q4 2024$0.05Beat by $0.40

Ask the moment Emergent Biosolutions reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Emergent Biosolutions report Q1 2026 earnings?
Emergent Biosolutions (EBS) reported Q1 2026 earnings on April 30, 2026 after market close.
What were Emergent Biosolutions's Q1 2026 revenue and EPS?
Emergent Biosolutions reported revenue of $156.1M and eps of $0.21 for Q1 2026.
Did Emergent Biosolutions beat estimates in Q1 2026?
Revenue beat the consensus estimate of $145.0M by $11.1M. EPS beat the consensus estimate of $-0.25 by $0.46.
How did Emergent Biosolutions's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 29.7% from $222.2M a year earlier and eps declined 70.4% from $0.71.
Where can I find Emergent Biosolutions's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001367644-26-000051) and the 10-Q periodic report (0001367644-26-000065) directly on SEC EDGAR. The filing index links above go to sec.gov.